These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. [The role of myelin oligodendrocyte glycoprotein antibodies for detection of demyelinating optic neuritis]. Wei SH; Zhao Y Zhonghua Yan Ke Za Zhi; 2017 Nov; 53(11):874-877. PubMed ID: 29141393 [TBL] [Abstract][Full Text] [Related]
28. Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD). Diem L; Hammer H; Hoepner R; Pistor M; Remlinger J; Salmen A Int Rev Neurobiol; 2022; 164():129-178. PubMed ID: 36038203 [TBL] [Abstract][Full Text] [Related]
30. Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review. Cellina M; Fetoni V; Ciocca M; Pirovano M; Oliva G Neuroradiol J; 2018 Feb; 31(1):69-82. PubMed ID: 28379073 [TBL] [Abstract][Full Text] [Related]
31. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C Front Immunol; 2021; 12():647618. PubMed ID: 33796113 [No Abstract] [Full Text] [Related]
33. Optic neuritis in the era of biomarkers. Chen JJ; Pittock SJ; Flanagan EP; Lennon VA; Bhatti MT Surv Ophthalmol; 2020; 65(1):12-17. PubMed ID: 31425702 [TBL] [Abstract][Full Text] [Related]
34. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369 [TBL] [Abstract][Full Text] [Related]
35. Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. Molazadeh N; Filippatou AG; Vasileiou ES; Levy M; Sotirchos ES J Neuroimmunol; 2021 Nov; 360():577702. PubMed ID: 34547512 [TBL] [Abstract][Full Text] [Related]
36. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690 [TBL] [Abstract][Full Text] [Related]
37. Diagnostic Criteria for Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and Myelin Oligodendrocyte Glycoprotein-immunoglobulin G-associated Disease. Filippi M; Preziosa P; Margoni M; Rocca MA Neuroimaging Clin N Am; 2024 Aug; 34(3):293-316. PubMed ID: 38942518 [TBL] [Abstract][Full Text] [Related]